Publicaciones en colaboración con investigadores/as de Macquarie University (10)

2023

  1. Comparison of the Accuracy of the 7-Item HADS Depression Subscale and 14-Item Total HADS for Screening for Major Depression: A Systematic Review and Individual Participant Data Meta-Analysis

    Psychological Assessment, Vol. 35, Núm. 2, pp. 94-114

  2. Gaps in clinical research in frontotemporal dementia: A call for diversity and disparities–focused research

    Alzheimer's and Dementia, Vol. 19, Núm. 12, pp. 5817-5836

2022

  1. Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials

    Clinical Cancer Research, Vol. 28, Núm. 10, pp. 2050-2060

2021

  1. An appraisal of respiratory system compliance in mechanically ventilated covid-19 patients

    Critical Care, Vol. 25, Núm. 1

  2. Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice

    The Journal of urology, Vol. 206, Núm. 2, pp. 240-251

  3. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    The Lancet Oncology, Vol. 21, Núm. 12, pp. 1574-1588

  2. Nivolumab + ipilimumab (N+I) vs sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (aRCC) dans l’étude CheckMate 214 : suivi à 4 ans et analyse en sous-groupe des patients (pts) non néphrectomisés

    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, Vol. 30, Núm. 13, pp. 785-786

  3. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 4-year follow-up of the phase III CheckMate 214 trial

    ESMO Open, Vol. 5, Núm. 6

2018

  1. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma

    New England Journal of Medicine, Vol. 378, Núm. 14, pp. 1277-1290